Bioleap

We're a Pharmatech company, leveraging a systems-modelling approach to develop the next generation of biologics. By leveraging a combination of AI and Physics, we've solved one of the key challenges of building large complex biophysical models. This presents us with a paradigm shift in our ability to take a rational approach to finding the optimal modalities of therapeutics to take forward into development, as we can infer previously unknown properties about these therapies and simulate all possible options to find the most efficacious, whilst retaining full mechanistic understanding of how and why they work. The 85-90% attrition rate at clinical trial for immuno-oncology therapies, which costs pharma $50billion+ year in failed trials, has been attributed to the lack of quality predictive pre-clinical models. We believe that a systems-based approach to in-silico modelling is the clear-cut solution to this problem. Our patent-pending technology reduces parameter uncertainty by up to 100x compared with existing biophysical or AI approaches, reducing data requirements by 10-20x. This is an order of magnitude shift, unlocking new possibilities for in-silico modelling of large-scale complex disease systems. This patent-pending innovation is at the core of Bioleap's mission. Our culture is one of open-ness. To challenge, to innovation, to research. Collaboration, breaking barriers, removing silos - with rigorous scientific intention and creative endeavour. We're taking on the greatest challenges facing biology. For that we're going to need the brightest minds - creating an ecosystem that provides the necessary environment to solve problems that have never been solved before.